📈 GH Secretagogue Blend

GHRP-2 + CJC-1295 No DAC Blend (10 mg) Dosage Protocol

The GHRP-2 + CJC-1295 No DAC blend (5 mg each) combines a potent GHRP with a GHRH analog for synergistic pulsatile GH release. GHRP-2 triggers GH secretion via ghrelin receptors; CJC-1295 No DAC amplifies the GH pulse amplitude via GHRH receptors — the two pathways act synergistically at the same pituitary somatotrope cells.

⚡ Quickstart Highlights

Reconstitution

3.0 mL BAC water → 3.33 mg/mL total (1.67 mg/mL each)

Per-Dose Range

100–300 mcg of each peptide

1 U-100 Unit =

33.3 mcg total (16.7 mcg each)

Frequency

2–3× daily

Dosing & Reconstitution Guide

Route: Subcutaneous | Frequency: 2–3× daily on empty stomach

Week	Dose Per Injection	Frequency	U-100 Units	Notes
Weeks 1–2	100 mcg each (200 mcg total)	Twice daily	6 units	Starting dose
Weeks 3–4	200 mcg each (400 mcg total)	Twice daily	12 units
Weeks 5–12	200–300 mcg each	2–3× daily	12–18 units	Full protocol

GHRP-2 elevates cortisol and prolactin at higher doses — unlike ipamorelin. Monitor if using at 300 mcg+ doses per injection. The GHRP-2/CJC-1295 combination produces one of the most potent GH responses of any secretagogue pairing due to GHRP-2's dual pituitary/hypothalamic action.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water into a sterile syringe.
Inject slowly down the inside glass wall of the vial; avoid foaming.
Gently swirl until dissolved. Do not shake.
Label with reconstitution date. Refrigerate at 2–8°C; use within 28 days.

Supplies Planning

Item	8 Weeks (200 mcg 2×/day)	12 Weeks
GHRP-2+CJC blend vials (10 mg)	5–6 vials	8–9 vials
Insulin syringes (30–50 unit)	112	168
BAC water (10 mL)	2 × 10 mL	3 × 10 mL
Alcohol swabs	2 × 100-pack	3 × 100-pack

Mechanism of Action

This blend combines GHRP-2's ghrelin receptor (GHS-R1a) agonism — which activates GH secretion from both the pituitary and hypothalamus — with CJC-1295 No DAC's GHRH receptor agonism, which amplifies GH pulse amplitude. The two mechanisms converge synergistically on pituitary somatotrope cells, producing GH pulses substantially larger than either compound alone.

GHRP-2 is chosen over ipamorelin in this blend for its potency — it is one of the most efficacious GHRPs studied. The trade-off is potential cortisol and ACTH elevation at doses ≥300 mcg, which ipamorelin avoids. For protocols where cortisol management is important, the CJC-1295 + Ipamorelin blend is preferred.

Research Findings & Safety Profile

Synergistic GH amplification: complementary receptor pathways produce greater GH release than either alone.
GHRP-2 acts on ghrelin receptors at both pituitary and hypothalamus (dual-site, high potency).
CJC-1295 No DAC acts on GHRH receptors to amplify pulse amplitude and extend pulse duration.
Cortisol/ACTH elevation possible with GHRP-2 at ≥300 mcg doses — monitor in extended protocols.
Strong appetite stimulation from GHRP-2 component — time injections before planned meals.
WADA prohibited. Not FDA approved.

Storage

State	Temperature	Duration	Notes
Lyophilized	−20°C (−4°F)	Up to 24 months	Dry, dark conditions
Reconstituted	2–8°C (35–46°F)	Up to 28 days	Avoid freeze-thaw; protect from light

⚠ Research Use Only: GHRP-2 component produces cortisol elevation at higher doses — preferred alternative is CJC-1295 + Ipamorelin if adrenal axis interference is a concern. WADA prohibited.

References

Bowers CY et al. 'Synergistic release of GH by GHRP and GHRH' — J Clin Endocrinol Metab View source ↗

See GHRP-2 and CJC-1295 No DAC individual protocol references